

INTERMOLECULAR INC
Form 8-K
September 05, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 04, 2017

Intermolecular, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

3011 N. First Street

San Jose, California
(Address of Principal Executive Offices)

001-35348 20-1616267
(Commission (IRS Employer

File Number) Identification No.)

95134
(Zip Code)

Edgar Filing: INTERMOLECULAR INC - Form 8-K

(408) 582-5700

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 1.02. TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT

On September 4, 2017, Intermolecular, Inc. (the “Company”) ended its consulting letter agreement (the “Agreement”) with its Chairman, Dr. Bruce M. McWilliams. Pursuant to the Agreement, Dr. McWilliams received compensation for assisting the Company with various of its priority initiatives.

In accordance with the terms of the Agreement, Dr. McWilliams’ compensation under the Company’s non-employee director compensation program will be reinstated.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

The information set forth in Item 1.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERMOLECULAR,
INC.

Date: September 05, 2017 By: /s/ Bill Roeschlein
Bill Roeschlein
Chief Financial Officer